A lthough epidemiological and clinical studies conducted over the last 40 years have identified variables which became well accepted "classical" coronary heart disease (CHD) risk factors (such as increased cholesterol and low-density lipoprotein (LDL) cholesterol levels, diabetes, hypertension, smoking, etc.), 1,2 it was also obvious that these parameters had limited ability to discriminate for CHD events. 3 Therefore, which additional lifestyle or biological variables could help identify, at reasonable costs in clinical practice, individuals at increased risk of CHD remains a question of considerable importance. 4
See pages 1868 and 1874In this regard, we have moved in lipidology beyond the following simple sequence of events (hyperlipidemia, atherosclerosis, CHD) as it is now recognized that acute coronary syndromes are the consequence of a complex interplay between the presence of known or unknown risk factors and atherosclerosis. 5 For instance, factors modulating the balance between fibrinolysis and thrombosis are also involved, 6 and considerable evidence has been published over the last decade to support the notion that CHD also has an inflammatory component. 7 Largely driven by the pioneering work of Ridker and colleagues, 8 -10 results of epidemiological studies, of primary and secondary prevention studies as well as of trials conducted in patients with acute coronary syndromes, have revealed that the plasma concentration of a relatively simple marker of inflammation, C-reactive protein (CRP), could predict the risk of a first or a recurrent coronary event, beyond the contribution of classical risk factors. 11 Whether CRP, an acute phase protein, plays a direct role in the etiology of CHD or whether it is only a marker of a dysmetabolic milieu that contributes to the patient's inflammatory profile is under investigation, but it is clear that CRP is currently the hottest new marker of CHD risk. 11 Therefore, the study of factors responsible for elevated CRP concentrations is an important topic both from public health and clinical perspectives. Accordingly, which therapeutic modalities may optimally reduce inflammation (and its most popular marker, CRP) is the object of considerable attention.Among the documented correlates of an inflammatory profile, it has become evident that obesity, 12 especially abdominal obesity, 13 is associated with elevated CRP concentrations. This situation could be explained by the increased production of inflammatory cytokines (interleukin [IL]-6 and tumor necrosis factor [TNF]-␣) by the expanded abdominal adipose depot of overweight/obese patients. 14 For instance, the production of CRP by the liver is stimulated by IL-6, 15 and adipose tissue becomes a major source of circulating IL-6 in abdominally obese patients. 16,17 Accordingly, intervention studies have shown that weight loss can indeed reduce circulating CRP levels, the reduction being proportionate to the magnitude of weight loss. 18,19 Another identified correlate of CRP concentrations is the level of physical acti...